• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氯米帕明、自我暴露及治疗师辅助暴露用于强迫仪式行为

Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals.

作者信息

Marks I M, Lelliott P, Basoglu M, Noshirvani H, Monteiro W, Cohen D, Kasvikis Y

机构信息

Institute of Psychiatry, Denmark Hill, London.

出版信息

Br J Psychiatry. 1988 Apr;152:522-34. doi: 10.1192/bjp.152.4.522.

DOI:10.1192/bjp.152.4.522
PMID:3167404
Abstract

A randomised treatment design for 49 chronically obsessive-compulsive ritualising patients was devised and three controlled comparisons were made. 1. During 7 weeks of self-exposure instructions, clomipramine treatment improved some measures of rituals and depression significantly more than did placebo medication; this effect was transient and disappeared as drug treatment and exposure were continued for a further 15 weeks. 2. During 11-16 weeks of clomipramine treatment, self-exposure instructions yielded highly significantly more patient improvement than did anti-exposure instructions on nearly all measures of rituals and some of social adjustment. 3. Adding therapist-aided exposure (1.3 hours) to self-exposure instructions (3 hours) after 8 weeks had a barely significant transient effect of dubious clinical value, which was lost by the end of exposure (at week 23) and during follow-up assessments to week 52. We conclude that of the three therapeutic factors tested, self-exposure was the most potent; clomipramine played a limited adjuvant role, and therapist-aided exposure a marginal one.

摘要

针对49名患有慢性强迫性仪式行为的患者设计了一种随机治疗方案,并进行了三项对照比较。1. 在7周的自我暴露指导期间,氯米帕明治疗在改善仪式行为和抑郁的某些指标方面比安慰剂药物显著更有效;但这种效果是短暂的,随着药物治疗和暴露持续15周后消失。2. 在氯米帕明治疗的11至16周期间,自我暴露指导在几乎所有仪式行为指标和一些社会适应指标上比反暴露指导产生了显著得多的患者改善效果。3. 在8周后,在自我暴露指导(3小时)基础上增加治疗师辅助暴露(1.3小时)产生了一个几乎不显著的短暂效果,其临床价值存疑,在暴露结束时(第23周)以及到第52周的随访评估期间这种效果消失了。我们得出结论,在测试的三个治疗因素中,自我暴露是最有效的;氯米帕明起到了有限的辅助作用,而治疗师辅助暴露的作用微不足道。

相似文献

1
Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals.氯米帕明、自我暴露及治疗师辅助暴露用于强迫仪式行为
Br J Psychiatry. 1988 Apr;152:522-34. doi: 10.1192/bjp.152.4.522.
2
Clomipramine and exposure for obsessive-compulsive rituals: i.氯米帕明与强迫仪式行为的暴露:一
Br J Psychiatry. 1980 Jan;136:1-25. doi: 10.1192/bjp.136.1.1.
3
Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.暴露及氯米帕明治疗强迫症后的六年随访
J Clin Psychiatry. 1991 Apr;52(4):150-5.
4
Clomipramine and exposure for chronic obsessive-compulsive rituals: III. Two year follow-up and further findings.氯米帕明与慢性强迫仪式行为的暴露:III. 两年随访及进一步发现
Br J Psychiatry. 1982 Jan;140:11-8. doi: 10.1192/bjp.140.1.11.
5
Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.氯米帕明用于接受暴露疗法的强迫仪式行为患者:剂量、血药浓度、疗效及副作用之间的关系
Psychopharmacology (Berl). 1988;95(1):113-8. doi: 10.1007/BF00212778.
6
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.暴露与仪式预防、氯米帕明及其联合治疗强迫症的随机安慰剂对照试验。
Am J Psychiatry. 2005 Jan;162(1):151-61. doi: 10.1176/appi.ajp.162.1.151.
7
[Behavior psychotherapy in obsessive-compulsive disorders].[强迫症的行为心理治疗]
Encephale. 1990 Jul-Aug;16 Spec No:341-6.
8
Discontinuing obsessive-compulsive disorder medication with behavior therapy.通过行为疗法停用强迫症药物
Am J Psychiatry. 1994 Dec;151(12):1842. doi: 10.1176/ajp.151.12.1842a.
9
Review of behavioral psychotherapy, I: Obsessive-compulsive disorders.行为心理治疗综述,I:强迫症
Am J Psychiatry. 1981 May;138(5):584-92. doi: 10.1176/ajp.138.5.584.
10
Obsessive-compulsive beliefs and treatment outcome.强迫观念与治疗结果。
Psychol Med. 1988 Aug;18(3):697-702. doi: 10.1017/s0033291700008382.

引用本文的文献

1
Non-union bone fractures.非愈合性骨折。
Nat Rev Dis Primers. 2021 Aug 5;7(1):57. doi: 10.1038/s41572-021-00289-8.
2
Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder.随机、安慰剂对照试验,评估认知行为疗法单独或联合舍曲林治疗儿童强迫症的疗效。
Behav Res Ther. 2013 Dec;51(12):823-9. doi: 10.1016/j.brat.2013.09.007. Epub 2013 Oct 10.
3
An update on the efficacy of psychological therapies in the treatment of obsessive-compulsive disorder in adults.
成人强迫症治疗中心理疗法疗效的最新进展。
J Obsessive Compuls Relat Disord. 2013 Apr 1;2(2):207-218. doi: 10.1016/j.jocrd.2013.02.005.
4
Design and Rationale for a Randomized Controlled Trial Testing the Efficacy of Aerobic Exercise for Patients with Obsessive-Compulsive Disorder.一项测试有氧运动对强迫症患者疗效的随机对照试验的设计与原理
Ment Health Phys Act. 2012 Dec 1;5(2):155-165. doi: 10.1016/j.mhpa.2012.06.002. Epub 2012 Jun 30.
5
Nonpharmacological treatments for anxiety disorders.焦虑症的非药物治疗
Dialogues Clin Neurosci. 2002 Sep;4(3):305-19. doi: 10.31887/DCNS.2002.4.3/jcottraux.
6
Exposure-in-vivo containing interventions to improve work functioning of workers with anxiety disorder: a systematic review.暴露于体内干预以改善焦虑障碍患者的工作功能:系统评价。
BMC Public Health. 2010 Oct 11;10:598. doi: 10.1186/1471-2458-10-598.
7
Effectiveness and cost-effectiveness of an exposure-based return-to-work programme for patients on sick leave due to common mental disorders: design of a cluster-randomized controlled trial.一项针对因常见精神障碍而病假的患者的基于暴露的重返工作项目的有效性和成本效益:一项整群随机对照试验的设计
BMC Public Health. 2009 May 13;9:140. doi: 10.1186/1471-2458-9-140.
8
Cognitive behavioral therapy for obsessive-compulsive disorder: an update.强迫症的认知行为疗法:最新进展
Curr Psychiatry Rep. 2005 Aug;7(4):268-73. doi: 10.1007/s11920-005-0080-x.
9
Talk that works: the rise of cognitive behaviour therapy.有效的谈话:认知行为疗法的兴起
BMJ. 1996 Dec 14;313(7071):1501-2. doi: 10.1136/bmj.313.7071.1501.
10
The brain in obsessive-compulsive disorder.强迫症中的大脑。
J Neurol Neurosurg Psychiatry. 1995 Nov;59(5):457-9. doi: 10.1136/jnnp.59.5.457.